Every acquisition begins with a number. Six to eighteen months later, a meaningful share of deals underperform their model, and the postmortem almost never blames the number itself. We think that is the wrong autopsy.
Every acquisition begins with a number. ARR, pipeline coverage, logo count, net revenue retention. The number gets underwritten, modelled, and turned into a valuation. Then, six to eighteen months later, a meaningful share of deals underperform their model, and the post-mortem almost never blames the number itself. It blames execution, a change in market conditions, or a new leadership team that did not integrate well.
We think that is the wrong autopsy. In most of these cases, the number was already fragile before the deal closed. It just had not been tested yet. The buyer inherited a machine that could produce the number once, under the seller's care, and assumed that meant it could produce the number again, under anyone's care. Those are two different claims, and standard diligence only checks the first one.
Financial diligence verifies that revenue was recognised correctly under accounting standards. Legal diligence verifies that contracts exist, are enforceable, and do not hide liabilities. Both disciplines are rigorous, and both are looking backward: did the number that was reported actually happen, and is it clean.
Neither discipline is built to ask a forward-looking question: is the commercial engine that produced this number structurally capable of producing it again, under different ownership, without the specific people, relationships, and quiet workarounds that generated it the first time?
That question is what we call Commercial Investment Risk, and it lives in the gap between the number is real and the number is repeatable. A business can pass every financial and legal check with no exceptions and still be running on a pipeline that is mostly dead weight, a discount approval process that is invisibly cannibalising margin every quarter, a founder whose personal relationships are propping up half the logo base, or a growth story that looks fine in aggregate and falls apart the moment you cut it by cohort.
None of this shows up in a quality of earnings report, because a QoE report is checking whether the historical P&L is accurate, not whether the underlying commercial behaviour that generated it will survive a change of hands. It does not show up in legal diligence either, because there is nothing illegal about a comp plan that quietly rewards short-term bookings over long-term retention. The business is compliant. It is just fragile, and compliance and fragility are not opposites.
We call this pattern, a business that looks well-governed and clean on paper while its commercial engine is structurally weak, Compliance Theater. It is rarely fraud and rarely even deliberate. It is what happens when reporting systems, incentive structures, and growth narratives get optimised for how they read in a board deck rather than for whether they will hold up under new ownership, a new CFO, or a downturn. The moment someone unfamiliar with the business's informal workarounds takes over, the gap between the reported number and the real capability becomes visible, usually within two or three quarters.
Our framework for finding these gaps before close, rather than after, is called the Behavioural Commercial Model (BCM). The premise is straightforward: revenue is not a static figure sitting in a spreadsheet, it is the output of ongoing human behaviour. Sales reps behave a certain way because of how they are compensated. Managers approve certain discounts because of how their own targets are structured. Finance teams categorise certain deals as committed because of pressure from above to hit a forecast. Every one of those behaviours is rational given the incentives in place, and every one of them can quietly distort the number that ends up in the data room.
If you want to know whether a revenue number will hold up, you cannot just audit the number. You have to reconstruct the behaviour that produced it and ask whether that behaviour is a sustainable pattern or a one-time artefact of a specific team, a specific quarter, or a specific set of relationships that will not survive the transaction.
We apply the BCM through two diagnostics, used at different points in a deal.
The Commercial Stress Test (CST) is a fast, structured screen, typically completed in days rather than weeks, designed for early-stage triage. It is built for the moment when a deal team needs to know whether commercial risk is likely enough to warrant a deeper look before committing more time and cost to the process. It does not produce a full picture. It produces a flag: proceed with standard diligence, or escalate to a full diagnostic.
The Commercial Diagnostic Assessment (CDA) is the full-depth version, used later in process when real money is about to move and the investment committee needs an actual answer rather than a flag. It works systematically through all eight failure modes, typically involves structured interviews with sales leadership and reps, not just management, a cohort-level cut of the data rather than an aggregate view, and a review of the actual comp plan and discount approval mechanics rather than the summarised version in the CIM.
Across both diagnostics, we look for the same eight recurring failure modes. We group them into four clusters based on where in the commercial system they originate, and those four clusters are the four tracks of this Knowledge Library.
Examining how data is recorded, reported, and distorted at the point of entry.
Everything downstream of the CRM inherits whatever distortion happens at the point of entry. If a rep marks a dead deal as late stage to protect their forecast credibility, that distortion flows into the pipeline coverage ratio, into the sales capacity model, and eventually into the growth assumptions in the investment thesis. This track is about catching the distortion at the source rather than trying to reverse-engineer it from the output.
Two failure modes live here. Zombie Pipeline describes deals that stay open in the CRM long after they are functionally dead, because closing them out would shrink the pipeline coverage number a rep or manager is being measured against. Vaporware LOI describes letters of intent or verbal commitments that were never realistically going to convert, but that get counted in the forecast anyway because they make near-term numbers look better. Both failure modes are about the same underlying mechanic: data entry incentives that reward optimism over accuracy.
How compensation structures and discount behaviour erode the revenue line before it reaches the forecast.
Comp plans and discount approval workflows are two of the most powerful, and most rarely audited, levers in a commercial organisation. They shape how reps behave every single day, whether or not anyone designed them with that outcome in mind. A comp plan that pays heavily on new logo bookings and lightly on renewal or expansion will produce reps who chase new logos at the expense of the install base, even if the plan document says nothing explicit about deprioritising existing customers.
Two failure modes live here. Cohort Decay is the slow, often invisible erosion of retained value within a customer cohort over time, the kind of thing that looks fine in an aggregate net revenue retention number but reveals a real problem the moment you split retention out by signing cohort or by account tier. Contract Cliff describes the sharp edge where contracts come up for renewal on materially worse terms than the original deal implied, often because discounting was used aggressively to win the deal in the first place and the renewal simply reverts toward list price, or because usage-based pricing structures were underestimated at signing.
The assumptions that break when a business grows: single-point dependencies, hero performers, and process gaps disguised as culture.
Founder-led and early-stage businesses often run on a set of informal, high-trust arrangements that work brilliantly at a small scale and are frequently mistaken for a repeatable go-to-market system. The tell is usually a phrase like that is just how we do things here, used to describe something that is actually one person's relationships or one channel's momentum, not an institutional capability.
Two failure modes live here. Founder Cliff describes revenue that depends disproportionately on a single leader's personal relationships, credibility, or hands-on involvement in deals, dressed up in materials as a scalable sales motion. Channel Mirage describes growth that is attributed to a channel or go-to-market motion that appears repeatable, but is actually dependent on a narrow set of conditions, a specific partner relationship, or a specific market moment that will not reproduce itself post-close. Both failure modes share the same underlying risk: the business's growth engine is a person or a moment, not a process.
What it takes to fix commercial infrastructure after the deal closes.
Not every failure mode is caught pre-close, and even the ones that are caught still need to be fixed. This track covers two failure modes that tend to surface in the market sizing and competitive narrative, and it is also where we get practical about remediation rather than just diagnosis, because a buyer who has already closed needs a plan, not just a post-mortem.
TAM Inflation describes a total addressable market that was sized generously to support a growth story, often by including adjacent markets the business has no realistic path to serving, rather than being grounded in a defensible, reachable market. Phantom Moat describes defensibility that gets asserted in the pitch, switching costs, network effects, proprietary technology, but that does not hold up under real scrutiny of the competitive landscape and customer switching behaviour. Both failure modes distort not the historical number but the growth assumption sitting on top of it, which matters enormously for anyone underwriting a multiple on future growth rather than trailing performance.
Together, these eight failure modes, Zombie Pipeline, Vaporware LOI, Cohort Decay, Contract Cliff, Founder Cliff, Channel Mirage, TAM Inflation, Phantom Moat, form S.L.A.M.'s proprietary taxonomy for Commercial Investment Risk. Every article in this Knowledge Library, and every Commercial Autopsy, maps back to one or more of them.
If you are new here, you do not need to read all 52 articles in order. Start with the track that matches where you sit today. Forensic, if you are mid-diligence and trying to sanity-check a pipeline report or forecast confidence level. Incentive Architecture, if you are staring at a comp plan or discount matrix that does not quite add up. Scaling Fiction, if you are evaluating a founder-led business and trying to work out how much of the growth is the founder. Operational Remediation, if you have already closed and are now trying to work out what to fix first.
From there, the related patterns links on each article will guide you sideways into adjacent failure modes; the eight rarely appear in isolation, and a business with Zombie Pipeline often has a comp plan quietly rewarding it. The four Commercial Autopsies show the taxonomy applied to real, anonymised and composited deal scenarios end to end, and are worth reading once you have the vocabulary from a track or two under your belt.
This library exists because we think Commercial Investment Risk deserves the same rigour that financial and legal risk already get, and right now it mostly does not. Everything that follows is our attempt to close that gap, one failure mode at a time.
Every article and Commercial Autopsy in the library maps back to this taxonomy. Explore the full Knowledge Library to see it in practice.